KemPharm, Inc. (NASDAQ:KMPH) Shares Bought by Arete Wealth Advisors LLC

Arete Wealth Advisors LLC boosted its stake in shares of KemPharm, Inc. (NASDAQ:KMPHGet Rating) by 24.6% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 75,932 shares of the specialty pharmaceutical company’s stock after buying an additional 14,978 shares during the period. Arete Wealth Advisors LLC owned 0.22% of KemPharm worth $382,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC acquired a new position in KemPharm during the fourth quarter worth $26,000. ProShare Advisors LLC acquired a new position in KemPharm during the fourth quarter worth $100,000. Russell Investments Group Ltd. acquired a new position in KemPharm during the first quarter worth $66,000. City State Bank acquired a new position in KemPharm during the fourth quarter worth $71,000. Finally, Strategic Asset Management LLC boosted its stake in KemPharm by 16.7% during the first quarter. Strategic Asset Management LLC now owns 40,087 shares of the specialty pharmaceutical company’s stock worth $202,000 after buying an additional 5,739 shares during the last quarter. Institutional investors and hedge funds own 32.39% of the company’s stock.

KemPharm Stock Performance

NASDAQ:KMPH opened at $6.44 on Friday. KemPharm, Inc. has a 52 week low of $4.00 and a 52 week high of $10.80. The stock’s fifty day moving average is $4.88 and its two-hundred day moving average is $5.18.

KemPharm (NASDAQ:KMPHGet Rating) last posted its earnings results on Thursday, May 12th. The specialty pharmaceutical company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). KemPharm had a negative return on equity of 0.28% and a negative net margin of 0.60%. The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $3.07 million. On average, equities research analysts anticipate that KemPharm, Inc. will post -0.27 EPS for the current fiscal year.

KemPharm Company Profile

(Get Rating)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.

Featured Stories

Want to see what other hedge funds are holding KMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for KemPharm, Inc. (NASDAQ:KMPHGet Rating).

Institutional Ownership by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.